Parkinson’s Foundation Invests $3.4 Million in Research Grants

The Parkinson’s Foundation today announced a $3.4 million investment across 34 research grants to advance promising Parkinson’s disease (PD) research. Grants support Parkinson’s research across a variety of disciplines for scientists who are actively studying various aspects of Parkinson’s with the hope of making life better for people with the disease and ultimately, leading to a cure.

“The Parkinson’s Foundation continues to provide these annual grant opportunities especially during the COVID-19 pandemic to ensure that PD research can successfully move forward,” said John L. Lehr, President and Chief Executive Officer of the Parkinson’s Foundation. “These research grants are critical to driving better patient outcomes and ensuring a better future for people with Parkinson’s disease.”

Parkinson’s Foundation research grants fund a diverse array of research studies that provide pre and postdoctoral researchers with training opportunities and established scientists and clinicians with the support to test innovative ideas that can lead to impactful research findings in the Parkinson’s field.

“With the support of the Parkinson’s Foundation, we hope to better understand how the nervous system functions as it relates to people with advanced Parkinson’s disease experience freezing gait, an inability to move their feet, during demanding or particularly stressful situations,” said Kevin Wilkins, Ph.D., a postdoctoral grant recipient. “We hope to develop ways to identify those at risk of developing cognitive and walking impairments as their disease progresses and provide the key to better therapies.”

This year the Foundation invested $450,000 in Impact Award programs. This award supports high-risk, high-reward projects that discover more about the biology of Parkinson’s and new treatments to people with Parkinson’s. Impact Award recipients received a maximum of $150,000 for approximately one year.

“These research grants allow us to better understand Parkinson’s disease and move the needle forward for better care and therapies for people with PD,” said James Beck, PhD, Chief Scientific Officer of the Parkinson’s Foundation. “We are thrilled to support these highly-promising grant recipients as they advance research towards a cure.”

Parkinson’s Foundation research investments are selected through a competitive application process and peer-reviewed by a panel that includes scientific experts and Foundation-trained research advocates. Since 1957, the Foundation has invested more than $365 million in Parkinson’s research and clinical care.

Research award categories include independent investigator awards, fellowships and early career awards, collaborative fellowships awards and Parkinson’s Foundation Research Centers awards. For more information about Parkinson’s Foundation research grants, visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”